Voyageur Pharmaceuticals Ltd. (VM.V)
CAD 0.11
(50.0%)
CAD 0.11
(50.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 40 Thousand CAD | 56.74% |
| 2022 | 25.52 Thousand CAD | 0.0% |
| 2021 | 25.52 Thousand CAD | -42.69% |
| 2020 | 44.52 Thousand CAD | 84.82% |
| 2019 | 24.09 Thousand CAD | -85.92% |
| 2018 | 171.06 Thousand CAD | 309.8% |
| 2017 | 41.74 Thousand CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 40 Thousand CAD | 0.0% |
| 2024 Q1 | 40 Thousand CAD | 0.0% |
| 2024 Q3 | - CAD | 0.0% |
| 2023 Q2 | 25.52 Thousand CAD | 0.0% |
| 2023 Q3 | 25.52 Thousand CAD | 0.0% |
| 2023 Q4 | 40 Thousand CAD | 56.74% |
| 2023 FY | 40 Thousand CAD | 56.74% |
| 2023 Q1 | 25.52 Thousand CAD | 0.0% |
| 2022 Q3 | 25.52 Thousand CAD | 0.0% |
| 2022 Q4 | 25.52 Thousand CAD | 0.0% |
| 2022 FY | 25.52 Thousand CAD | 0.0% |
| 2022 Q1 | 25.52 Thousand CAD | 0.0% |
| 2022 Q2 | 25.52 Thousand CAD | 0.0% |
| 2021 Q1 | 44.33 Thousand CAD | -0.43% |
| 2021 Q2 | 42.8 Thousand CAD | -3.46% |
| 2021 Q3 | 42.07 Thousand CAD | -1.71% |
| 2021 Q4 | 25.52 Thousand CAD | -39.34% |
| 2021 FY | 25.52 Thousand CAD | -42.69% |
| 2020 Q3 | 59.37 Thousand CAD | 0.0% |
| 2020 Q2 | 59.37 Thousand CAD | 162.22% |
| 2020 Q1 | 22.64 Thousand CAD | -6.01% |
| 2020 FY | 44.52 Thousand CAD | 84.82% |
| 2020 Q4 | 44.52 Thousand CAD | -25.01% |
| 2019 Q2 | 28.69 Thousand CAD | -7.27% |
| 2019 FY | 24.09 Thousand CAD | -85.92% |
| 2019 Q4 | 24.09 Thousand CAD | -8.77% |
| 2019 Q3 | 26.4 Thousand CAD | -7.95% |
| 2019 Q1 | 30.94 Thousand CAD | -81.91% |
| 2018 Q3 | 130.91 Thousand CAD | 249.0% |
| 2018 Q1 | 39.64 Thousand CAD | -5.03% |
| 2018 FY | 171.06 Thousand CAD | 309.8% |
| 2018 Q4 | 171.06 Thousand CAD | 30.67% |
| 2018 Q2 | 37.51 Thousand CAD | -5.38% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 FY | 41.74 Thousand CAD | 0.0% |
| 2017 Q4 | 41.74 Thousand CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | 583.58 Thousand CAD | 93.146% |
| CanadaBis Capital Inc. | 5.91 Million CAD | 99.324% |
| Decibel Cannabis Company Inc. | 32.34 Million CAD | 99.876% |
| Delivra Health Brands Inc. | 1.78 Million CAD | 97.759% |
| Entourage Health Corp. | 5.79 Million CAD | 99.31% |
| Lifeist Wellness Inc. | 868.65 Thousand CAD | 95.395% |
| Cannara Biotech Inc. | 39.73 Million CAD | 99.899% |
| Medicure Inc. | 229 Thousand CAD | 82.533% |
| PharmaCielo Ltd. | 2.55 Million CAD | 98.433% |
| Rubicon Organics Inc. | - CAD | -Infinity% |
| BioSyent Inc. | 1.03 Million CAD | 96.145% |